Special Issue "Optical Genome Mapping in Hematological Malignancies"
Deadline for manuscript submissions: 15 January 2023 | Viewed by 4381
Interests: genetics genomics & proteomics; cancer
Interests: genomic technologies; immuno-genomics
Interests: cancer; tumor biology; pathology and biomarkers epilepsy; neurology genetics; environmental factors hematology; blood and marrow transplantation
For more than 40 years, the clinical evaluation of structural variation in hematological malignancies has primarily been driven by karyotyping. Karyotyping is a robust tool for evaluating structural and numerical changes in leukemia and other malignancies due to its ability to visualize and catalogue recurrent changes to chromosomes. As a result, many types of leukemia and lymphoma have a cytogenetic (i.e., karyotyping-based) classification system for diagnosis and prognosis. However, karyotyping suffers from several challenges, including the need for dividing cells (metaphases) and the relatively “low resolution” of the technique. Thus, ancillary testing, such as FISH or RT-PCR, is required to identify specific rearrangements between genes. Optical Genome Mapping is a new technology that can detect structural variation within a sample at a much higher resolution than karyotyping. As such, it is a promising new technique for the clinical evaluation of chromosomal changes in hematologic malignancies.
The aim of this Special Issue is stimulate discussion around the use and adoption of Optical Genome Mapping for clinical diagnostics in hematological malignancies.
- Carry out the evaluation of optical genome mapping in different types of hematologic malignancies compared to conventional approaches or other novel technologies for structural and molecular classification;
- Introduce interpretative systems, software tools, or other bioinformatics approaches to improve data analysis and reporting in hematologic malignancies;
- Provide technical improvements or processes in hematologic malignancies that compare pre-analytical or analytical components in optical genome mapping to improve analysis, diagnostic sensitivity, etc.;
- Produce novel research findings that may lead to novel diagnostic insights in the future.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- Myeloid neoplasms;
- Lymphoid neoplasms;
- Plasma cell disorders;
- Technical papers;
- Economic utility analysis of OGM vs. other technologies;
- Clinical research discoveries.
We look forward to receiving your contributions.
Dr. Adam C. Smith
Dr. Alex Hoischen
Dr. Gordana Raca
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Optical genome mapping
- Myeloid neoplasia
- Lymphoid neoplasia
- Structural Variation